Matteo Santamaria

Matteo Santamaria

Auto-generated profile, based on publicly available information

Matteo Santamaria

Cardiovascular and Arrhythmias Department "Gemelli Molise", Campobasso, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2008 in Circulation
Verified
Journal Article
Closed access
CCCorrado Carbucicchio
Corrado Carbucicchio
MSMatteo Santamaria
Matteo Santamaria
NTNicola Trevisi
Nicola Trevisi
GMGiuseppe Maccabelli
Giuseppe Maccabelli
FGFrancesco Giraldi
Francesco Giraldi
PBPaolo Della Bella
Paolo Della Bella
Background— Electrical storm (ES) caused by recurrent episodes of ventricular tachycardia (VT) can cause sudden death in patients with implantable cardioverter-defibrillators and adversely affects prognosis in survivors. Catheter ablation has been proposed for treating ES, but its long-term effect in a large population has never been verified. Methods and Results— Ninety-five consecutive patients with coronary artery disease (72 patients), idiopathic dilated cardiomyopathy (10 patients), and arrhythmogenic right ventricular dysplasia/cardiomyopathy (13 patients) undergoing catheter ablation for drug-refractory ES were prospectively evaluated. Short-term efficacy was defined by a complete protocol of programmed electric stimulation and by in-hospital outcome; long-term analysis addressed ES recurrence, cardiac mortality, and VT recurrence. Pleomorphic/nontolerated VTs required electroanatomic and noncontact mapping in 48 and 22 patients, respectively, and percutaneous cardiopulmonary support in 10 patients. An epicardial approach was used in 10 patients. After 1 to 3 procedures, induction of any clinical VT(s) by programmed electrical stimulation was prevented in 85 patients (89%). ES was acutely suppressed in all patients; a minimum period of 7 days with stable rhythm was required before hospital discharge. At a median follow-up of 22 months (range, 1 to 43 months), 87 patients (92%) were free of ES and 63 patients (66%) were free of VT recurrence. Eight of 10 patients with persistent inducibility of clinical VT(s) had ES recurrence; 4 of them died suddenly despite appropriate implantable cardioverter-defibrillator intervention. All together, 11 of 95 patients (12%) died of cardiac-related reasons. In the group of patients presenting with all clinical VTs acutely abolished, no ES recurrence was documented, and cardiac mortality was significantly lower compared with the group of patients showing ≥1 clinical VT still inducible after catheter ablation. Conclusions— Advanced strategies of catheter ablation applied to a large population of patients are effective in the short-term treatment of ES. By preventing ES recurrence, catheter ablation may play a protective role over the long term and, together with long-term pharmacological therapy, may favorably affect cardiac mortality.

13 June 2016 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
CSC. Sardu
C. Sardu
MSM. Santamaria
M. Santamaria
MRMaria Rosaria Rizzo
Maria Rosaria Rizzo
MBMichelangela Barbieri
Michelangela Barbieri
MMM. di Marino
M. di Marino
RMR. Marfella
R. Marfella

1 January 2007 in JACC
Verified
Journal Article
Closed access
GLGiovanna Liuzzo
Giovanna Liuzzo
MSMatteo Santamaria
Matteo Santamaria
LBLuigi M. Biasucci
Luigi M. Biasucci
MNMichela Narducci
Michela Narducci
VCValeria Colafrancesco
Valeria Colafrancesco
FCFilippo Crea
Filippo Crea

1 May 2017 in The American Journal of Cardiology
Verified
Journal Article
Closed access
CSCelestino Sardu
Celestino Sardu
Gaetano SantulliGaetano Santulli
Gaetano Santulli
MSMatteo Santamaria
Matteo Santamaria
MBMichelangela Barbieri
Michelangela Barbieri
CSCosimo Sacra
Cosimo Sacra
MRMaria Rosaria Rizzo
Maria Rosaria Rizzo

22 October 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
Celestino SarduCelestino Sardu
Celestino Sardu
Pasquale PaolissoPasquale Paolisso
Pasquale Paolisso
CSCosimo Sacra
Cosimo Sacra
MSMatteo Santamaria
Matteo Santamaria
Claudio De LuciaClaudio De Lucia
Claudio De Lucia
Raffaele MarfellaRaffaele Marfella
Raffaele Marfella
Objectives: To evaluate clinical outcomes in patients with diabetes, treated by cardiac resynchronization therapy with a defibrillator (CRT-d), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) in addition to conventional hypoglycemic therapy vs. CRTd patients under conventional hypoglycemic drugs. Background: Patients with diabetes treated by CRTd experienced an amelioration of functional New York Association Heart class, reduction of hospital admissions, and mortality, in a percentage about 60%. However, about 40% of CRTd patients with diabetes experience a worse prognosis. Materials and methods: We investigated the 12-months prognosis of CRTd patients with diabetes, previously treated with hypoglycemic drugs therapy (n 271) vs. a matched cohort of CRTd patients with diabetes treated with GLP-1 RA in addition to conventional hypoglycemic therapy (n 288). Results: At follow up CRTd patients with diabetes treated by GLP-1 RA therapy vs. CRTd patients with diabetes that did not receive GLP-1 RA therapy, experienced a significant reduction of NYHA class (p value < 0.05), associated to higher values of 6 min walking test (p value < 0.05), and higher rate of CRTd responders (p value < 0.05). GLP-1 RA patients vs. controls at follow up end experienced lower AF events (p value < 0.05), lower VT events (p value < 0.05), lower rate of hospitalization for heart failure worsening (p value < 0.05), and higher rate of CRTd responders (p value < 0.05). To date, GLP-1 RA therapy may predict a reduction of AF events (HR 0.603, CI [0.411–0.884]), VT events (HR 0.964, CI [0.963–0.992]), and hospitalization for heart failure worsening (HR 0.119, CI [0.028–0.508]), and a higher CRT responders rate (HR 3.707, CI [1.226–14.570]). Conclusions: GLP-1 RA drugs in addition to conventional hypoglycemic therapy may significantly reduce systemic inflammation and circulating BNP levels in CRTd patients with diabetes, leading to a significant improvement of LVEF and of the 6 min walking test, and to a reduction of the arrhythmic burden. Consequently, GLP-1 RA drugs in addition to conventional hypoglycemic therapy may reduce hospital admissions for heart failure worsening, by increasing CRTd responders rate. Trial registration NCT03282136. Registered 9 December 2017 “retrospectively registered”

10 November 2015 in Pharmacogenomics
Verified
Journal Article
Closed access
Celestino SarduCelestino Sardu
Celestino Sardu
MSMatteo Santamaria
Matteo Santamaria
Giuseppe PaolissoGiuseppe Paolisso
Giuseppe Paolisso
RMRaffaele Marfella
Raffaele Marfella
Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresponder patients. microRNAs (miRs) have been used as AF fibrotic and electrical alterations biomarkers. miRs may differentiate responders patients to ablative approach. Selective miR target therapy, as upregulation by adenovirus transfection and/or miR downregulation by antagomiR, may be used to treat AF patients. Catheter ablation of triggering electrical pulmonary veins activity or fibrotic areas defragmentation may be upgraded by miR therapy to prevent cardiac electrical and fibrotic remodeling after AF ablation.